Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
Clinical trial NCT02939989 · COMPLETED
Trial details
- NCT number
- NCT02939989
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-21
- Primary completion
- 2021-05-07
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.